Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134, (Summary Text)
